



MAYZENT[®] (siponimod): Information for female patients of childbearing potential

Contents

Before starting MAYZENT[®]	3
While you are taking MAYZENT[®]	4
After stopping MAYZENT[®]	6
Contact details of your doctor	7

Before starting MAYZENT[®]



MAYZENT[®] must not be used in pregnant women or in women of childbearing potential not using effective contraception.



Before starting treatment, a pregnancy test must be conducted in women of childbearing potential and a negative result verified by a doctor.

Talk with your doctor about reliable methods of birth control that you must use during treatment and for at least 10 days after you stop MAYZENT[®] treatment.

Please read the MAYZENT[®] Patient and Caregiver Guide provided by your doctor.

While you are taking MAYZENT®



While taking MAYZENT® you must not become pregnant.

You must use effective methods of birth control during treatment and for at least 10 days after you stop treatment.



If you plan to become pregnant, please talk with your doctor as you will need to stop treatment. Your doctor will provide counselling about potential risks of MAYZENT® to the foetus, and will discuss the possible return of disease activity with you.

Tell your doctor immediately if you become pregnant while taking MAYZENT® because treatment will have to be stopped. Your doctor will discuss the possible return of disease activity with you.

You will also be provided with follow-up medical examinations (e.g. ultrasonography examination).

While you are taking MAYZENT®



Should a pregnancy occur during treatment with MAYZENT®, please report it to your doctor.

Your doctor might inform Novartis about it so as to monitor the outcomes of pregnancy in women exposed to MAYZENT® during pregnancy.

After stopping MAYZENT®



Effective methods of birth control must be used for at least 10 days after you stop MAYZENT® treatment.



Should a pregnancy occur within 10 days following discontinuation of treatment please report it to your doctor.

Your doctor might inform Novartis about it so as to monitor the outcomes of pregnancy in women exposed to MAYZENT® during pregnancy.

Inform your doctor immediately if you believe your MS is getting worse (e.g. weakness or visual changes) or if you notice any new symptoms after stopping treatment with MAYZENT®.

Contact details of your doctor

[Add name and contact details of doctor here]

HSA Approved RMP - Mayzent Patient Pregnancy Guide

This material is also available online. Please scan this QR code or visit <https://www.medhub.novartis.com.sg/ermp/mayzent>



Mayzent is a registered trademark of Novartis Pharma AG



Novartis (Singapore) Pte Ltd
20 Pasir Panjang Road,
#10-25/28 Mapletree Business City,
Singapore 117439
Phone: +65 6722 6010 • Fax: +65 6323 4335 • www.novartis.com

This document has been approved by HSA as of 26-APR-2021 .

FA-11236876

Date of approval: 25th JUL 2024

Version 2 .1 | Printed Jul 2024